Patnaik stressed early diagnosis, rapid treatment, and aggressive surveillance as the backbone of elimination efforts
Acquisition strengthens integrated radiology and pathology capabilities, enhancing access to advanced diagnostics and preventive healthcare
New Shoolagiri plant strengthens Maiva’s global CDMO capabilities with advanced isolator technology, flexible production lines, and expanded capacity for complex injectable therapies
Samelisant will be the centerpiece of Suven’s scientific presence
The decision was driven by results from the Phase III CAPItello-281 trial,
Health Ministry reviews progress, highlights targeted interventions in high-burden states, and calls for stronger surveillance and stigma reduction to achieve a leprosy-free India
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
The regulatory decision follows promising results from RIVER-81
Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.
Approval is based on results from the phase 3 OASIS 4 clinical trial
Subscribe To Our Newsletter & Stay Updated
